Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Fihr Chaudhary"'
Autor:
Catherine C. Smith, Aaron C. Logan, Kimberly C. Lin, Fihr Chaudhary, Theodore C. Tarver, Makoto Ando, Daisuke Terada, Timothy T. Ferng
Supplementary Data from The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a9928a2c3a0bd8101cd6ef406ce88a1
https://doi.org/10.1158/1535-7163.22522783
https://doi.org/10.1158/1535-7163.22522783
Autor:
Catherine Dianne Quinn, Fihr Chaudhary, Aron Gould-Simon, Baorong Chen, Harsimran Singh Bhandal, Uzair Chaudhary
Publikováno v:
The American journal of case reports. 23
BACKGROUND Neuroendocrine neoplasms are commonly seen in association with hormone production, and clinical signs that arise from these hormonal effects often manifest as the first presentation of malignancy. The excess production of parathyroid hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a334bc93723114295438fa6c981057
https://pubmed.ncbi.nlm.nih.gov/35849548
https://pubmed.ncbi.nlm.nih.gov/35849548
Autor:
Timothy T. Ferng, Daisuke Terada, Makoto Ando, Theodore C. Tarver, Fihr Chaudhary, Kimberly C. Lin, Aaron C. Logan, Catherine C. Smith
Publikováno v:
Cancer Research. 82:LB516A-LB516A
Background: FLT3 tyrosine kinase inhibitors (TKIs) such as midostaurin and gilteritinib have improved clinical outcomes for patients with FLT3-mutant acute myeloid leukemia (AML), but resistance remains a problem. FF-10101 is the first irreversible,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3f1d57490981fbd0b82e4755f66806d
https://doi.org/10.1158/1538-7445.am2022-lb516a
https://doi.org/10.1158/1538-7445.am2022-lb516a
Autor:
Timothy T. Ferng, Daisuke Terada, Makoto Ando, Theodore C. Tarver, Fihr Chaudhary, Kimberly C. Lin, Aaron C. Logan, Catherine C. Smith
Publikováno v:
Mol Cancer Ther
Molecular cancer therapeutics, vol 21, iss 5
Molecular cancer therapeutics, vol 21, iss 5
Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance remains an important clinical problem. FF-10101 is the first irreversib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25519900feb9bb267129ada77ad0dded
https://pubmed.ncbi.nlm.nih.gov/35395091
https://pubmed.ncbi.nlm.nih.gov/35395091
Autor:
Matthew Lee, Omar Mahmood, Uzair B. Chaudhary, Mir Ali, Mohammed Sani Bukari, Tanner Mortenson, Fihr Chaudhary, Sanjay Hinduja
Publikováno v:
Journal of Clinical Oncology. 38:e16067-e16067
e16067 Background: The clinical and mutational profile of Hispanic patients with metastatic colon cancer is not well documented. In this retrospective study, we aim to describe the clinical and mutational profile of Hispanic patients with metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa47aa494e355a0209a9e2af0792e1ae
https://doi.org/10.1200/jco.2020.38.15_suppl.e16067
https://doi.org/10.1200/jco.2020.38.15_suppl.e16067